D.C. biotech Vanda Pharmaceuticals acquires AnaptysBio’s drug for rare skin disorder
D.C.’s Vanda Pharmaceuticals Inc. has locked in a deal with a West Coast biotech to commercialize a drug for a rare skin ...
Analyst Expectations For AnaptysBio's Future
Analysts have recently evaluated AnaptysBio and provided 12-month price targets. The average target is $36.17, accompanied by ...
Shareholders in AnaptysBio (NASDAQ:ANAB) are in the red if they invested three years ago
AnaptysBio, Inc. ( NASDAQ:ANAB ) shareholders should be happy to see the share price up 13% in the last month. But ...
Pharmaceutical Technology6d
Vanda and AnaptysBio link for generalised pustular psoriasis therapy
Vanda and AnaptysBio have announced an exclusive worldwide licence agreement to develop and commercialise imsidolimab to ...
Fintel on MSN6d
Wolfe Research Initiates Coverage of AnaptysBio (ANAB) with Outperform Recommendation
Fintel reports that on February 4, 2025, Wolfe Research initiated coverage of AnaptysBio (NasdaqGS:ANAB) with a Outperform ...
Wedbush Sticks to Its Buy Rating for AnaptysBio (ANAB)
Wedbush analyst David Nierengarten maintained a Buy rating on AnaptysBio (ANAB – Research Report) today and set a price target of $40.00. The ...
AnaptysBio’s (ANAB) Outperform Rating Reiterated at Wedbush
AnaptysBio (NASDAQ:ANAB – Get Free Report)‘s stock had its “outperform” rating reaffirmed by equities researchers at Wedbush in a research note issued to investors on Monday,RTT News reports. They ...
ETF Daily News5d
AnaptysBio’s (ANAB) Neutral Rating Reiterated at HC Wainwright
AnaptysBio (NASDAQ:ANAB – Get Free Report)‘s stock had its “neutral” rating reissued by analysts at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They currently have ...